BLUE News and Press, bluebird bio Inc. From 03/26/22

About a third of biotech companies will have one year of cash or less by the end of 2022, the Morgan Stanley analysts led by Matthew Harrison said this week based on a sample of 380 firms. While the number of companies requiring cash is similar to the levels seen before 2018 – 21, the ...

CRSP needs to make tough decisions regarding the loss of critical CRISPR patents in the US. CRSP differentiates itself by creating allogeneic CAR-T therapy allowing mass production, off-shelf availability, and potentially low production cost. The company is the wealthiest CRISPR b...

PTAB turned the CRISPR industry upside down, with sleepy biotechs becoming market favorites overnight and leading companies dropping by double-digit rates. NTLA management will likely talk down the effects of the patent ruling, but given the new dynamics, this speculative trade has be...

Shares of the gene therapy specialist Bluebird Bio (NASDAQ: BLUE) are having another rough session today. Specifically, the biotech's stock is down by 11% as of 12:56 p.m. ET on Monday. Bluebird's shares are retreating today in response to two key issues: Image source: Getty...

Gainers: Clover Health Investments (NASDAQ:CLOV) +18%. Monte Rosa Therapeutics (NASDAQ:GLUE) +12%. Sharecare (NASDAQ:SHCR) +10%. InflaRx (NASDAQ:IFRX) +9%. Sigilon Therapeutics (NASDAQ:SGTX) +9%. Losers: Atreca (NASDAQ:BCEL) -30%. Biophytis (NASDAQ:BPTS) -14%. Alpine Immun...

Bluebird bio (NASDAQ:BLUE) is trading ~17% lower in the pre-market Monday after the commercial-stage biotech company announced the resignation of its Chief Financial Officer, Gina Consylman, effective Apr. 03. Consylman gave the notice of her resignation on Mar. .04, Bluebird bio (B...

Suzhou antibody company Adagene will apply its masking technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights (ex-Japan) for two Heidelberg Pharma ADC candidates with options on two more in a deal potentia...

bluebird bio (NASDAQ:BLUE) is scheduled to announce Q4 earnings results on Monday, March 7th, after market close. The consensus EPS Estimate is -$1.74 (+42.2% Y/Y) and the consensus Revenue Estimate is $5.72M (-46.6% Y/Y). Over the last 1 year, BLUE has beaten EPS estimates 0% of the time and...

bluebird bio (NASDAQ:BLUE) saw its Q4 2021 net loss narrow ~22% as it posted product revenue for the first time. Its quarterly net loss was ~$155.1M, or -$2.14 per basic and diluted share. The company reported $1.4M in product revenue from its gene therapy beti-cel (betibeglogene autotemcel) ...

- The Company’s first two gene therapies, beti-cel for β-thalassemia and eli-cel for cerebral adrenoleukodystrophy, under review by the FDA - - lovo-cel BLA submission for sickle cell disease remains on track for Q1 2023 - - Ended year with $442M in r...